Affiliation:
1. Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033
Abstract
ABSTRACT
Against 307 pneumococci of various resistotypes, dalbavancin MICs were 0.008 to 0.125 μg/ml. All strains were susceptible to vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin. Dalbavancin at 2× MIC was bactericidal against all 10 pneumococci tested after 24 h. Vancomycin and teicoplanin killed 10 and 8 strains, respectively, at 2× MIC after 24 h.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference24 articles.
1. Anderegg, T. R., D. J. Biedenbach, and R. N. Jones. 2003. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397) an investigational glycopeptide with potent gram-positive activity. Antimicrob. Agents Chemother.41:2795-2796.
2. Candiani, G., M. Abbondi, M. Borgonovi, G. Romanò, and F. Parenti. 1999. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother.44:179-192.
3. Cercenado, E., F. Garcia-Garrote, and E. Bouza. 2001. In-vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J. Antimicrob. Chemother.47:77-81.
4. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med.341:233-239.
5. Antipneumococcal Activities of Gemifloxacin Compared to Those of Nine Other Agents
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献